Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27967307 | 0.82 | KDM4E (0.65) | TDP1SIRT3KDM4EALDH1A1MAPT | |
| SCHEMBL31227538 | 0.81 | SIRT3 (0.58) | TDP1SIRT3PARP1KDM4EF7 | |
| Hydrochloric Acid SCHEMBL27967302 | 0.81 | KDM4E (0.62) | TDP1SIRT3KDM4EALDH1A1MAPT | |
| SCHEMBL4186883 | 0.80 | KDM4E (0.65) | TDP1PARP1KDM4EHTTALDH1A1 | |
| SCHEMBL1571384 | 0.79 | MKNK1 (0.55) | TDP1SIRT3PARP1KDM4EF7 | |
| SCHEMBL29575496 | 0.79 | MKNK1 (0.55) | TDP1SIRT3PARP1KDM4EF7 | |
| SCHEMBL31032109 | 0.78 | SIRT3 (0.58) | TDP1SIRT3PARP1KDM4EF7 | |
| SCHEMBL31660092 | 0.78 | PARP1 (0.50) | TDP1PARP1KDM4EMKNK2ALDH1A1 | |
| SCHEMBL28019336 | 0.78 | MKNK1 (0.58) | TDP1SIRT3F7F3SARM1 | |
| SCHEMBL16059482 | 0.78 | PARP1 (0.50) | TDP1PARP1KDM4EMKNK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | claimed |
| EP-1503993-A4 | COMPOUNDS, METHODS AND COMPOSITIONS | CYTOKINETICS INC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20040077662-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | claimed |
| EP-1539727-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | CYTOKINETICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7482343-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1539727-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7166595-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1556357-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7041676-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1539727-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040116400-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082567-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077662-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004006865-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003106426-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077662-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | TDP1 1037/4885SIRT3 2876/4885PARP1 954/4885 |
| US-20070135432-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | TDP1 1037/4885SIRT3 2876/4885PARP1 954/4885 |
| US-20040082567-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | TDP1 879/4885SIRT3 2556/4885PARP1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.